Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-15
2008-07-15
Hayes, Robert C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
10807414
ABSTRACT:
Methods and compositions are provided for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), or for protecting nerves from glutamate toxicity, which comprises administering to an individual in need thereof an effective amount of the copolymer poly-Glu,Tyr.
REFERENCES:
patent: 6835711 (2004-12-01), Eisenbach-Schwartz et al.
patent: 2003/0003082 (2003-01-01), Eisenbach-Schwartz et al.
patent: 99/34827 (1999-07-01), None
patent: WO 03/002140 (2003-01-01), None
patent: WO03/047500 (2003-06-01), None
patent: WO 03/047500 (2003-06-01), None
patent: WO2004/060266 (2004-07-01), None
patent: WO2005/055920 (2005-06-01), None
Bussiere et al. 2001. In Functional Neurobiology of Aging, Hof and Mobbs (Eds.). pp. 77-84.
Kemperman 2002. Journal of Neuroscience 22:635-638.
Orr 2001. Genes and Development 15:925-932.
Cecil Textbook of Medicine, 2000, pp. 2092-2109.
Jackowski 1995. British Journal of Neurosurgery 9:303-317.
Al-Chalabi et al. 2000. Current Opinion in Neurology 13:397-405.
Cady et al, Response of Murine γδ T Cells to the Synthetic Polypeptide Poly-Glu50Tyr50,J Immunol165(4):1790-1798 (2000).
Drach et al, “Suppressive effect of synthetic polypeptide GT on the induction of delayed-type hypersensitivity to a complex GT + methylated bovine serum albumin”,Anriales D'Immunologie, France 131D(3):299-307 (1980).
Havenith et al, “T Cell Priming In Situ by Intratracheally Instilled Antigen-pulsed Dendritic Cells”,Am J Respir Cell Mol Biol9(5):484-488 (1993).
Lei et al, “Regulation of Immune Responses by I-J Gene Products; III. GT-specific Suppressor Factor is Composed of Separate I-J and Idiotype-bearing Chains”,J Immunol130(3):1274-1279 (1983).
Vidovic et al, “Recessive T Cell Response to Poly (Glu50Tyr50) Possibly Caused by Self Tolerance”,J Immunol134(6):3563-3568 (1985).
Hauben et al, (Sep. 1, 2000) “Passive or Active Immunization with Myelin Basic Protein Promotes Recovery from Spinal Cord Contusion,” The Journal of Neuroscience 20(17): 6421-6430.
Hauben et al, (Aug. 2001) “Posttraumatic Therapeutic Vaccination with Modified Myelin Self-Antigen Prevents Complete Paralysis While Avoiding Autoimmune Disease,” The Journal of Clinical Investigation 108(4): 591-599.
Fisher et al, (Jan. 1, 2001) “Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies,” The Journal of Neuroscience 21(1): 136-142.
Schori et al, (Mar. 13, 2001) “Vaccination for Protection of Retinal Ganglion Cells Against Death from Glutamate Cytotoxicity and Ocular Hypertension: Implications for Glaucoma,” PNAS 98)6): 3398-3403.
Sucher et al, (1997) “Molecular Basis of Glutamate Toxicity in Retinal Ganglion Cells,” Vision Res. 37(24): 3483-3493.
Schori et al,(2001) “T-Cell Based Immunity Counteracts the Potential Toxicity of Glutamate in the Central Nervous System,” Journal of Neuroimmunology. 119(2): 199-204.
Stedman's Medical Dictionary (2002), Physicians' Desk Reference, Medical Economics Company Inc.
Angelov et al, “Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral scierosis”,Proc Natl Acad Sci USA100(8):4790-4795 (2003).
Debré et al, “Genetic control of specific immune suppression. II.H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50(GT)”,J Exp Med142(6):1447-1454 (1975).
Hirschberg et al, “Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma”,J Neuroimmunol89(1-2):88-96 (1998).
Kipnis et al, “T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies,”,Proc Natl Acad Sci USA97(13):7446-7451 (2000).
Kipnis et al, “Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity”,J Neuroimmunol130(1-2):78-85 (2002).
Kipnis et al, “Neuroprotective autoimmunity: naturally occurring CD4+CD25+regulatory T cells suppress the ability to withstand injury to the central nervous system”,Proc Natl Acad Sci USA99(24):15620-15625 (2002).
Moalem et al, “Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy”,Nat Med5(1):49-55 (1999).
Schwartz et al, “Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries”,Trends Mol Med7(6):252-258 (2001).
Seo et al, “Activation of murine epidermal Vγ5/Vδ1-TCR+T cell lines by Glu-Tyr polypeptides”,J Invest Dermatol116(6):880-885 (2001).
Yoles et al, “Protective autoimmunity is a physiological response to CNS trauma”,J Neurosci21(11):3740-3748 (2001).
Eisenbach-Schwartz Michal
Hauben Ehud
Yoles Ester
Browdy and Neimark
Hayes Robert C.
Kolker Daniel E.
Yeda Research and Development Co. Ltd.
LandOfFree
Poly-Glu,Tyr for neuroprotective therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Poly-Glu,Tyr for neuroprotective therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Poly-Glu,Tyr for neuroprotective therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3919882